Pay in 4 interest-free payments of $6.72 Learn more
Ships within 48 hours · Estimated delivery Aug 25 - Aug 30
Given the limited published data on GLP-1 use in GDM, this platform provided the most relevant and up-to-date information, including ongoing studies with detailed protocols not yet available in peer-reviewed literature
Kailera Therapeutics recently announced that oral KAI-7535 had posted strong phase 3 results, albeit in China
It works by activating a thyroid hormone receptor that promotes reduction of fat buildup in the liver
there is no stability data for storing them pre-mixed
The most detailed published percentages still come from the 48-week Phase 2 trial, while the TRIUMPH Phase 3 program is the source researchers are watching for larger-sample confirmation of common adverse events, discontinuation rates, and rare safety signals
